Stock Track | PROCEPT BioRobotics Soars 11.56% in Night Session on Strong Q1 Earnings Beat and Upbeat Guidance

Stock Track04-30

PROCEPT BioRobotics Corporation (PRCT) saw its stock price surge 11.56% in night session trading on Thursday, following the release of its first-quarter 2026 financial results after market close on Wednesday.

The surgical robotics company reported quarterly revenue of $83.132 million, beating analyst estimates of $80.506 million and representing a 20% year-over-year increase. Adjusted EBITDA loss of $18.122 million also came in better than the expected $18.7 million loss, driven by strong U.S. system sales, improved pricing, and a 30% increase in U.S. procedures.

Investors reacted positively to the company's maintained full-year 2026 guidance, which projects revenue growth of 27% to 33%, and to the recent FDA clearance of its second-generation FirstAssist AI software for Aquablation therapy, which enhances the capabilities of its HYDROS robotic system. The combination of better-than-expected quarterly results and confidence in future growth prospects fueled the significant price movement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1131971457?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 12:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131971457","market":"sg","top_or_hot":-1,"title":"Stock Track | PROCEPT BioRobotics Soars 11.56% in Night Session on Strong Q1 Earnings Beat and Upbeat Guidance","media":"Stock Track","content":"<p>PROCEPT BioRobotics Corporation (PRCT) saw its stock price surge 11.56% in night session trading on Thursday, following the release of its first-quarter 2026 financial results after market close on Wednesday.</p><p>The surgical robotics company reported quarterly revenue of $83.132 million, beating analyst estimates of $80.506 million and representing a 20% year-over-year increase. Adjusted EBITDA loss of $18.122 million also came in better than the expected $18.7 million loss, driven by strong U.S. system sales, improved pricing, and a 30% increase in U.S. procedures.</p><p>Investors reacted positively to the company's maintained full-year 2026 guidance, which projects revenue growth of 27% to 33%, and to the recent FDA clearance of its second-generation FirstAssist AI software for Aquablation therapy, which enhances the capabilities of its HYDROS robotic system. The combination of better-than-expected quarterly results and confidence in future growth prospects fueled the significant price movement.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | PROCEPT BioRobotics Soars 11.56% in Night Session on Strong Q1 Earnings Beat and Upbeat Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | PROCEPT BioRobotics Soars 11.56% in Night Session on Strong Q1 Earnings Beat and Upbeat Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-30 12:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PROCEPT BioRobotics Corporation (PRCT) saw its stock price surge 11.56% in night session trading on Thursday, following the release of its first-quarter 2026 financial results after market close on Wednesday.</p><p>The surgical robotics company reported quarterly revenue of $83.132 million, beating analyst estimates of $80.506 million and representing a 20% year-over-year increase. Adjusted EBITDA loss of $18.122 million also came in better than the expected $18.7 million loss, driven by strong U.S. system sales, improved pricing, and a 30% increase in U.S. procedures.</p><p>Investors reacted positively to the company's maintained full-year 2026 guidance, which projects revenue growth of 27% to 33%, and to the recent FDA clearance of its second-generation FirstAssist AI software for Aquablation therapy, which enhances the capabilities of its HYDROS robotic system. The combination of better-than-expected quarterly results and confidence in future growth prospects fueled the significant price movement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRCT","symbol_name":"PROCEPT BioRobotics","start_time":0,"source_url":"","article_id":"1131971457","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131971457","pubTimestamp":1777523489,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"PROCEPT BioRobotics Corporation (PRCT) saw its stock price surge 11.56% in night session trading on Thursday, following the release of its first-quarter 2026 financial results after market close on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRCT":"PROCEPT BioRobotics"},"translate_title":"个股追踪|PROCEPT BioRobotics夜盘飙升11.56%，因强劲的Q1盈利超出预期和乐观指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRCT":1},"content_text":"PROCEPT BioRobotics Corporation (PRCT) saw its stock price surge 11.56% in night session trading on Thursday, following the release of its first-quarter 2026 financial results after market close on Wednesday.The surgical robotics company reported quarterly revenue of $83.132 million, beating analyst estimates of $80.506 million and representing a 20% year-over-year increase. Adjusted EBITDA loss of $18.122 million also came in better than the expected $18.7 million loss, driven by strong U.S. system sales, improved pricing, and a 30% increase in U.S. procedures.Investors reacted positively to the company's maintained full-year 2026 guidance, which projects revenue growth of 27% to 33%, and to the recent FDA clearance of its second-generation FirstAssist AI software for Aquablation therapy, which enhances the capabilities of its HYDROS robotic system. The combination of better-than-expected quarterly results and confidence in future growth prospects fueled the significant price movement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131971457","isCrawlerRequest":true}